Figure S12 from HDAC6 Inhibition Releases HR23B to Activate Proteasomes, Expand the Tumor Immunopeptidome and Amplify T-cell Antimyeloma Activity

Fig. S12. a. Effect of the top pharmacologics alone on E.G7-Ova cell viability as measured by LDH release into the culture medium (green). Also shown is the effect of pre-treating the B3Z cells with the pharmacologics then co-culturing with E.G7-Ova cells (red). b. Effect of pre- treatment of B3Z cells with pharmacologics followed by co-culture with E.G7-Ova cells. Cell viability was measured by annexin-V+ staining as above. c. Effect of HDAC6 inhibitors on E.G7-Ova viability. d. Effect of HDAC6 inhibitors on B3Z viability. e. Effect of HDAC6 inhibitors on E.G7-Ova viability after co-culture with B3Z cells at E:T 2:1.